IP Library Granted Patent US 12,162,865
Granted Patent B2
US 12,162,865 · App. 17/689,704 · Granted Dec 10, 2024

Methods of treating cancer

Inventors: Sarah K. Knutson (Lincoln, MA); Natalie Warholic (Cambridge, MA); Heike Keilhack (Belmont, MA)
Assignee: Epizyme, Inc.
C07D405/14A61K31/4412A61K31/4545A61K31/5377C07D211/86C07D405/12C12Q1/6886
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,162,865
App. No.
17/689,704
Granted
Dec 10, 2024
Kind
B2
Abstract

The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Claims (16)

1. A method of treating a human subject comprising administering to the human subject a compound:

or a pharmaceutically acceptable salt thereof;

wherein the human subject has reduced expression or loss of function of INI1 and epithelioid sarcoma.

2. The method of claim 1 , wherein the pharmaceutically acceptable salt is a hydrobromic acid salt.

3. The method of claim 1 , wherein the human subject has reduced expression of INI1.

4. The method of claim 2 , wherein the human subject has reduced expression of INI1.

5. The method of claim 1 , wherein the human subject has loss of function of INI1.

6. The method of claim 2 , wherein the human subject has loss of function of INI1.

7. The method of claim 3 , wherein reduced expression of INI1 is detected by an immunoassay.

8. The method of claim 4 , wherein reduced expression of INI1 is detected by an immunoassay.

9. The method of claim 5 , wherein loss of function of INI1 is determined by detecting any alteration in a nucleic acid sequence encoding INI1.

10. The method of claim 6 , wherein loss of function of INI1 is determined by detecting any alteration in a nucleic acid sequence encoding INI1.

11. The method of claim 5 , wherein loss of function is caused by a loss of function mutation.

12. The method of claim 6 , wherein loss of function is caused by a loss of function mutation.

13. The method of claim 9 , wherein loss of function is caused by a loss of function mutation.

14. The method of claim 10 , wherein loss of function is caused by a loss of function mutation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2022
From: KNUTSON, SARAH K.; WARHOLIC, NATALIE; KEILHACK, HEIKE
To: EPIZYME, INC.
Reel/Frame 059251/0535 →
Continuity (11)
Continuation 16749073 · Jan 22, 2020
Continuation 15979916 · May 15, 2018
Continuation 15598262 · May 17, 2017
Continuation 14054646 · Oct 15, 2013
Provisional Application 61786277 · Mar 14, 2013
Provisional Application 61780703 · Mar 13, 2013
Provisional Application 61758972 · Jan 31, 2013
Provisional Application 61714145 · Oct 15, 2012
Provisional Application 61714140 · Oct 15, 2012
Provisional Application 61714045 · Oct 15, 2012
Related Publication 20220315566A1 · Oct 6, 2022